Simon Barnett
Partner, Head of Research @ Dimension. Focused on Compute + Bio
New York, NY, US
Joined September 2025
Network
12.8K connectionsDSWCMD
NFATDS
KDJCJE
NGTKCW
BLAGRM
NFAT
JCMK
Summary
Simon Barnett is a Partner and Head of Research at Dimension, a firm focused on the intersection of life science and technology. He plays a foundational role in building and leading Dimension's research function, driving thesis building, market insight productization, diligence operations, and underwriting logic. His expertise spans life sciences research and investment management, bringing an insatiable curiosity for cutting-edge science and a relentless work ethic to his role. dimensioncap+3
With previous experience as Director of Life Sciences Research and Genomics Analyst at ARK Investment Management LLC, Simon has a strong background in public biotech investment and disruptive technologies. He led interdisciplinary teams, informed portfolio management, and published extensively on the digitization of the life sciences industry, demonstrating his deep understanding of innovative technologies and their market implications. syntheticbiologysummit+3
Simon is an active thought leader and writer, contributing to articles and posts on topics such as genome assembly, protein engineering, and multi-cancer early detection (MCED). His public commentary often involves drawing analogies between fields like machine learning and sequencing, showcasing a holistic and analytical approach to complex scientific and technological challenges. nitter+2
His scientific interests are broad and include novel biosensors, liquid biopsies, deep learning, and cell programming. He also harbors a specific passion for cancer screening and pediatric rare disease research, reflecting a commitment to impactful areas of life sciences. syntheticbiologysummit+1
Simon holds a Bachelor of Science in Chemical and Biomolecular Engineering from The Johns Hopkins University, which provides a strong technical foundation for his career at the intersection of biology and technology. His early career included roles in preclinical cancer research and medtech software engineering, demonstrating hands-on experience in the field. syntheticbiologysummit+1
Work
Education
Writing
Neural Network Potentials for Enabling Advanced Small-Molecule Drug Discovery and Generative Design
June 1, 2024A perspective published in GEN Biotechnology about the future of neural network potentials (NNPs) for small molecule discovery and design.
The View from ARK Invest
October 1, 2022An article published in GEN Biotechnology discussing investment perspectives from ARK Invest.
Genome Assembly at Warp Speed
August 1, 2021A 'Works in Progress' piece representing ARK's internal research process on de novo genome assembly algorithms and long-read sequencing technology, focusing on mdBG algorithm optimized for highly accurate long-read sequencing data.
Discussing Our Exact Sciences Valuation (Podcast)
A podcast episode where Simon Barnett discusses ARK's valuation of Exact Sciences and their outlook on the company's trajectory in cancer testing.